Trial · NCT04042623
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Incidence of Adverse Events (AEs) | 14 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | The Effect of AVB-S6-500 on Change From Baseline to End of Treatment in 24-hour Urine Protein Excretion (UPE) in g/Day. | 12 weeks | The subject discontinued the study before data were collected, hence the outcome measure was not analyzed. | ||
| PRIMARY | The Effect of AVB-S6-500 on Change From Baseline to End of Treatment in 24-hour Urine Protein Excretion (UPE) in g/Day in the Subset of Patients With Baseline High Proteinuria. | 12 weeks | The subject discontinued the study before data were collected, hence the outcome measure was not analyzed. | ||
| PRIMARY | The Effect of AVB-S6-500 on Proportion of Patients With Urinary Protein Equivalent of < 1 g/24 Hours at End of Treatment | 12 weeks | The subject discontinued the study before data were collected, hence the outcome measure was not analyzed. | ||
| PRIMARY | The Effect of AVB-S6-500 on Proportion of Patients Who Had at Least a Decrease of 0.5 g/Day Proteinuria From Baseline to End of Treatment. | 12 weeks | The subject discontinued the study before data were collected, hence the outcome measure was not analyzed. | ||
| PRIMARY | The Effect of AVB-S6-500 on Change From Baseline to End of Treatment in Urine Albumin/Creatinine Ratios (uACRs). | 12 weeks | The subject discontinued the study before data were collected, hence the outcome measure was not analyzed. | ||
| PRIMARY | The Effect of AVB-S6-500 on Change From Baseline to End of Treatment in Estimated Glomerular Filtration Rate (eGFR). | 12 weeks | The subject discontinued the study before data were collected, hence the outcome measure was not analyzed. | ||
| SECONDARY | Incidence of Anti-drug Antibody (ADA) | 14 weeks | The subject discontinued the study before data were collected, hence the outcome measure was not analyzed. | ||
| SECONDARY | Titers of Anti-AVB-S6-500 Antibodies | 14 weeks | The subject discontinued the study before data were collected, hence the outcome measure was not analyzed. | ||
| SECONDARY | Apparent Terminal Half-life (t1/2) of AVB-S6-500 | 12 weeks | Samples were not analyzed because the study was terminated by the Sponsor. | ||
| SECONDARY | Maximum Observed Plasma Concentration of AVB-S6-500 (Cmax) | 12 weeks | Samples were not analyzed because the study was terminated by the Sponsor. | ||
| SECONDARY | Area Under Time-concentration Curve (AUC) | 12 weeks | Samples were not analyzed because the study was terminated by the Sponsor. | ||
| SECONDARY | Time of Maximum Observed AVB-S6-500 Concentration (Tmax) | 12 weeks | Samples were not analyzed because the study was terminated by the Sponsor. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04042623/outcomes